Assessment of eGFR, using Cystatin-C and Creatinine Based Equations for the Early Detection of Renal Injury in Diabetic and Non Diabetic Patients

Sangeeta, S.; Ambekar, Jeevan G; Sudhakar, T; waz, Mohd Shanna; Dongre, Nilima N.

doi:10.7860/jcdr/2018/36698.12069

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As serum creatinine was unable to detect early decline in GFR owing to the fact that levels of serum creatinine begins to rise above normal range only in case of kidney had lost approximately 50% of its function. This proposes that serum cystatin-c levels are related to impairment in tubular function and in turn can be suggested as an early marker of kidney diseases 23 . Moreover, detecting CKD at early stage could be important for early intervention in order to be able to slow kidney function loss, which in turn helps improving survival and quality of life.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic efficacy of cystatin-c in association with different ACE genes predicting renal insufficiency in T2DM

Taha

Mahdy-Abdallah

Shahy

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Diabetic nephropathy (DN) seems to be the major cause of chronic kidney disease that may finally lead to End Stage Renal Disease. So, renal function assessment in type 2 diabetes mellitus (T2DM) individuals is very important. Clearly, DN pathogenesis is multifactorial and different proteins, genes and environmental factors can contribute to the onset of the disease. We assessed sensitive and specific biomarkers (in blood and urine) which can predict kidney disease susceptibility among T2DM patients. Serum cystatin-c (cyst-c) in blood and urinary hemeoxygenase (HO-1) in addition to ACE I/D polymorphism and ACE G2350A genotypes. Hundred and eight T2DM patients and 85 controls were enrolled. Serum cystatin-c and urinary (HO-1) were tested by ELISA. Genetic determination of both ACE I/D polymorphism and ACE G2350A genotypes was performed by PCR for all participants. Significant rise in serum cystatin-c and urinary HO-1 levels were shown in diabetic groups compared with control group. Moreover, GG genotype of ACE G2350A gene in diabetic group was associated with rise in serum cystatin-c and urinary HO-1 compared with control group. Mutant AA genotype demonstrated increase in urinary HO-1. DD polymorphism was associated with rise in serum creatinine and cyst-c in diabetic group. Positive correlation was seen between duration of diabetes and serum cyst-c and between serum glucose and urinary (HO-1) in diabetic group. The results from this study indicated an association of serum cystatin-c with GG genotype of ACE G2350A in conjugation with DD polymorphism of ACE I/D which could be an early predictor of tubular injury in T2DM diabetic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic efficacy of cystatin-c in association with different ACE genes predicting renal insufficiency in T2DM

Taha

Mahdy-Abdallah

Shahy

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The study population came from 5 continents and covered 10 different countries. Demographic and clinical data of the 14 incorporated studies are summarized in Table I [29][30][31][32][33][34][35][36][37][38][39][40][41][42]. All the included studies have a case-control design and have a clear method of diagnosis for T2DM.…”

Section: Study Characteristicsmentioning

confidence: 99%

Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis

Duan¹,

Huang²,

Tang³

2020

aoms

View full text Add to dashboard Cite

A b s t r a c tIntroduction: This study aimed to systemically summarize the present literature about circulating cystatin C (Cys C) levels in type 2 diabetes mellitus (T2DM) and provide a more precise evaluation of Cys C levels in T2DM. Material and methods: Relevant studies about Cys C concentrations in T2DM were searched in PubMed, EMBASE and the Cochrane Library database (up to Oct 31 2018). We computed the pooled standard mean difference (SMD) with its 95% confidence interval (CI) of Cys C levels through a random-effect model. The Q test and the I 2 statistic were used to assess and quantify between-study heterogeneity; publication bias was evaluated through a funnel plot and Egger's linear regression test. Results: After the literature search and screening process, 14 studies with 723 T2DM patients and 473 healthy controls were finally included in the meta-analysis. The results showed that T2DM patients had significantly higher Cys C levels compared to healthy controls (SMD = 1.39, 95% CI: 0.92-1.86, p < 0.001). Publication bias was not detected based on the symmetrical shape of the funnel plot and the results of Egger's test (p = 0.452). Subgroup analyses suggested that variables of human race, age, gender, study sample size and disease duration have a relationship with Cys C level in T2DM patients. Conclusions: Overall, our study suggests that patients with T2DM have an elevated circulating Cys C level compared to healthy controls, and it is associated with race, age, gender, study sample size and disease duration. Further investigations are still needed to explore the causal relationship of aberrant Cys C concentrations in T2DM.

show abstract

“…Recent research efforts have focused on linking Cystatin-C to onset and progression of cardiovascular and metabolic risk and disease, but most findings are based on small sample sizes and generalize poorly to diverse populations, thus limiting appropriate epidemiological inferences [ 14 , 23 , 24 ]. Limited work has examined links between Cystatin-C, mortality and diabetes and tested sex and race/ethnic modifications [ 25 – 28 ].…”

Section: Introductionmentioning

confidence: 99%

“…and generalize poorly to diverse populations, thus limiting appropriate epidemiological inferences [14,23,24]. Limited work has examined links between Cystatin-C, mortality and diabetes and tested sex and race/ethnic modifications [25][26][27][28].…”

Section: Introductionmentioning

confidence: 99%

Serum Cystatin-C is linked to increased prevalence of diabetes and higher risk of mortality in diverse middle-aged and older adults

et al. 2022

View full text Add to dashboard Cite

Objective Type 2 Diabetes Mellitus (henceforth diabetes) affects roughly 35 million individuals in the US and is a major risk factor for cardiovascular and kidney disease. Serum Cystatin-C is used to monitor renal function and detect kidney damage. Recent research has focused on linking Cystatin-C to cardiovascular risk and disease, but most findings focus on small sample sizes and generalize poorly to diverse populations, thus limiting epidemiological inferences. The aim of this manuscript is to study the association between Cystatin-C, diabetes, and mortality and test for possible sex or racial/ethnic background modifications in these relationships. Methods We analyzed 8-years of biennial panel data from Health and Retirement Study participants 50-years and older who self-identified as White (unweighted N (uN) = 5,595), Black (uN = 867), or Latino (uN = 565) for a total of uN = 7,027 individuals. We modeled diabetes and death over 8-years as function of baseline Cystatin-C (log transformed) adjusting for covariates and tested modifications in associations by race/ethnic background and sex. Results Mean log Cystatin-C at visit 1 was 0.03±0.32 standard deviation. A 10% increase in Cystatin-C levels was associated with 13% increased relative risk of diabetes at baseline (11% and 9% by years 4 and 8). A 10% increase in Cystatin-C was highly associated with increased relative risk of death (28% and 31% by years 4 and 8). These associations were present even after adjusting for possible confounders and were not modified by sex or racial/ethnic background. Conclusion Despite differential risks for diabetes and mortality by racial/ethnic groups, Cystatin-C was equally predictive of these outcomes across groups. Cystatin-C dysregulations could be used as a risk indicator for diabetes and as a warning sign for accelerated risk of mortality.

show abstract

Assessment of eGFR, using Cystatin-C and Creatinine Based Equations for the Early Detection of Renal Injury in Diabetic and Non Diabetic Patients

Cited by 3 publications

References 0 publications

Diagnostic efficacy of cystatin-c in association with different ACE genes predicting renal insufficiency in T2DM

Diagnostic efficacy of cystatin-c in association with different ACE genes predicting renal insufficiency in T2DM

Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis

Serum Cystatin-C is linked to increased prevalence of diabetes and higher risk of mortality in diverse middle-aged and older adults

Contact Info

Product

Resources

About